Battelle Pancake Breakfast

1
(No Transcript)
2
Key Applications of Genetic and Genomic Testing
(slide 1 of 2)

• Diagnosis of Disease Whereby genetic or genomic
  tests are used to screen a patient with a
  suspected disease (usually a hereditary genetic
  disease) to positively identify the disease. This
  is genetic or genomic testing applied to a
  symptomatic individual.
• Predictive Medicine The presymptomatic testing
  of individuals to determine the risk of
  developing adult onset diseases and disorders
  (such as for Huntingtons disease or breast
  cancer.)
• Genotyping of Specific Disease Such as the
  genotyping of a patients specific HIV strain or
  cancer tumor to guide therapeutic approaches.
• Pharmacogenomics Whereby genetic or genomic
  testing is used to optimize drug therapies based
  on the patients genotype and known genetic
  linkages to drug efficacy or toxicity.

3
Key Applications of Genetic and Genomic Testing
(slide 2 of 2)

• Identity Testing Whereby genetic testing assists
  in confidently establishing identity, providing
  individual genetic identification profiles. These
  profiles can be used to establish biological
  relatedness.
• Forensic Testing Whereby genetic testing is used
  to establish the identity of individuals based
  upon a specimen of blood, urine, or other tissue.
  
• Carrier Screening This involves testing
  unaffected individuals who carry one copy of a
  gene for a disease that requires two copies for
  the disease to be expressed.
• Newborn Screening Whereby newborns are screened
  shortly after birth for disorders that are
  treatable, but difficult to otherwise detect
  clinically.

4
Size of the Genetic and Genomic Testing Industry

• Total U.S. clinical laboratory testing market
  placed at 62 billion (Source G2)
• Needed to determine genetic and genomic testing
  component of this
• Survey deployed to clinical labs by Battelle
  determined genetic and genomic testing to be 9.5
  of the market (5.9 billion)
• Used econometric technique of input/output
  analysis to quantify direct and indirect impacts
  of the industry within the U.S.

5
Annual Economic Impact of the U.S. Genetic and
Genomic Testing Sector
Category of Impact Jobs Personal Income Value-Added Output (Business Volume) State/Local Tax Revenue FederalTax Revenue
Direct Impacts 43,563 2,504 3,221 5,890 98 448
Indirect Impacts 27,397 1,417 2,360 4,118 189 290
Induced Impacts 45,326 2,035 3,614 6,518 370 437
Total Impacts 116,286 5,956 9,195 16,526 657 1,175
Impact Multiplier 2. 7 2.4 2.9 2.8 6.7 2.6
Source Battelle analysis IMPLAN U.S. 2009
Model Personal Income Measures cash, benefits
and non-cash payments received by individuals in
the economy. Value-Added Represents the
difference between an industrys or an
establishments total output and the cost of its
intermediate inputs. Output Is the dollar value
of production (i.e., sales).
6
Key Functional Benefits of Genetic and Genomic
Testing
7
INTO THE FUTURE
P4 Medicine Personalized, Predictive,
Preventive, Participatory
Large-scale increases in available tests
Clinical application of whole genome sequencing
Significantly lowered disease burden
Healthier workforce and higher productivity
Genetic data-rich environment identifies targets
for drug discovery
Reduced time, cost and failure rate for clinical
trials
Opportunities to build on U.S. economic
leadership in an innovative sector
8
Contact

• Simon J. Tripp
• Senior Director
• Battelle Memorial Institute
• Technology Partnership Practice
• Phone [phone]
• E-mail tripps_at_battelle.org
• Report Authors
• Simon Tripp, Martin Grueber and Deborah Cummings